astrazeneca
Second-quarter profits before tax at British biopharmaceutical firm AstraZeneca were at $2.40 billion, the company reported on Thursday, 15% higher than last year's $2.09 billion. Earnings per share were $1.24, up 6% from last year's $1.17. Core earnings per share were $1.98, down 8% from the prior year. Total revenues for the second quarter grew 13% to $12.94 billion from last year's $11.42 billion. The growth was 17% at constant exchange rates. Further, the company has declared that interim dividend increased 7 cents to $1.00. The record date for the first interim dividend for 2024, payable ...
DPA International
Second-quarter profits before tax at British biopharmaceutical firm AstraZeneca were at $2.40 billion, the company reported on Thursday, 15% higher than last year's $2.09 billion. Earnings per share were $1.24, up 6% from last year's $1.17. Core earnings per share were $1.98, down 8% from the prior year. Total revenues for the second quarter grew 13% to $12.94 billion from last year's $11.42 billion. The growth was 17% at constant exchange rates. Further, the company has declared that interim dividend increased 7 cents to $1.00. The record date for the first interim dividend for 2024, payable ...
DPA Breaking News
Second-quarter profits before tax at British biopharmaceutical firm AstraZeneca were at $2.40 billion, the company reported on Thursday, 15% higher than last year's $2.09 billion. Earnings per share were $1.24, up 6% from last year's $1.17. Core earnings per share were $1.98, down 8% from the prior year. Total revenues for the second quarter grew 13% to $12.94 billion from last year's $11.42 billion. The growth was 17% at constant exchange rates. Further, the company has declared that interim dividend increased 7 cents to $1.00. The record date for the first interim dividend for 2024, payable ...
DPA
Eli Lilly (NYSE: LLY) has achieved a major milestone by securing regulatory approval for its weight management drug, Mounjaro, in China. This development, confirmed through the company’s official WeChat account, represents a significant expansion in Eli Lilly’s global footprint. The approval was granted by the National Medical Products Administration (NMPA), China’s regulatory authority for pharmaceuticals. Mounjaro is designed for individuals with a body mass index (BMI) greater than 24 kg/m² and at least one related medical condition, providing a new option for weight management. Eli Lilly h...
Invezz
The FTSE 100 index has moved sideways in the past two months and remains 3% below its highest point this year. It was trading at £8,200 on Thursday as investors focus on the next actions by the Bank of England (BoE) and the upcoming quarterly earnings by key companies. Bank of England’s next movesThe FTSE 100 index will be in the spotlight as investors focus on the BoE interest rate decision scheduled on August 1st. This will be an important meeting since the bank is expected to either cut rates or signal that it will cut in September. The BoE has successfully brought the UK headline inflation...
Invezz
AstraZeneca, the largest pharmaceutical group in Britain, announced that the U.S. Food and Drug Administration (FDA) has approved its lung cancer drug, Imfinzi, for use alongside other chemotherapy treatments. The approval is specifically for Imfinzi in combination with carboplatin and paclitaxel, followed by Imfinzi monotherapy. This regimen is intended for adults suffering from primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). Significant trial resultsThe approval follows a clinical trial that demonstrated Imfinzi’s efficacy in reducing the risk of di...
Invezz
British pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition of Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). AstraZeneca, through a subsidiary, has completed the acquisition of all outstanding shares of Fusion as per the definitive agreement. The acquisition was executed under a plan of arrangement, with each share priced at $21.00 in cash at closing and an additional non-transferable contingent value right of $3.00 per share in cash payable upon the attainment of a specified regulato...
DPA International
British pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition of Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). AstraZeneca, through a subsidiary, has completed the acquisition of all outstanding shares of Fusion as per the definitive agreement. The acquisition was executed under a plan of arrangement, with each share priced at $21.00 in cash at closing and an additional non-transferable contingent value right of $3.00 per share in cash payable upon the attainment of a specified regulato...
DPA
British pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition of Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). AstraZeneca, through a subsidiary, has completed the acquisition of all outstanding shares of Fusion as per the definitive agreement. The acquisition was executed under a plan of arrangement, with each share priced at $21.00 in cash at closing and an additional non-transferable contingent value right of $3.00 per share in cash payable upon the attainment of a specified regulato...
DPA Breaking News
Shares in AstraZeneca were slightly higher on Thursday despite an update on the European Medicines Agency's website on Wednesday stating the regulator said that the approval for AstraZeneca's Vaxzevria had been withdrawn “at the request of the marketing authorisation holder.” AstraZeneca's Covid-19 vaccine was first given the nod by the EMA in January 2021. Within weeks, however, concerns grew about the vaccine's safety, when dozens of countries suspended the vaccine's use after unusual but rare blood clots were detected in a small number of immunised people. The EU regulator concluded AstraZe...
Euronews (English)
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら